PE20071037A1 - SALTS AND FORMULATIONS OF 1- [5- (4-AMINO-7-ISOPROPYL-7H-PYRROLO [2,3-d] PYRIMIDIN-5-CARBONYL) -2-METOXY-PHENYL] -3- (2,4-DICHLORO -PHENIL) -UREA - Google Patents
SALTS AND FORMULATIONS OF 1- [5- (4-AMINO-7-ISOPROPYL-7H-PYRROLO [2,3-d] PYRIMIDIN-5-CARBONYL) -2-METOXY-PHENYL] -3- (2,4-DICHLORO -PHENIL) -UREAInfo
- Publication number
- PE20071037A1 PE20071037A1 PE2006001565A PE2006001565A PE20071037A1 PE 20071037 A1 PE20071037 A1 PE 20071037A1 PE 2006001565 A PE2006001565 A PE 2006001565A PE 2006001565 A PE2006001565 A PE 2006001565A PE 20071037 A1 PE20071037 A1 PE 20071037A1
- Authority
- PE
- Peru
- Prior art keywords
- phenyl
- urea
- metoxy
- pyrrolo
- pyrimidin
- Prior art date
Links
- -1 4-AMINO-7-ISOPROPYL-7H-PYRROLO [2,3-d] PYRIMIDIN-5-CARBONYL Chemical class 0.000 title abstract 3
- 239000004202 carbamide Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 2
- 229920000609 methyl cellulose Polymers 0.000 abstract 2
- 239000001923 methylcellulose Substances 0.000 abstract 2
- 235000010981 methylcellulose Nutrition 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 229920000642 polymer Polymers 0.000 abstract 2
- 239000007962 solid dispersion Substances 0.000 abstract 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 abstract 1
- 239000006185 dispersion Substances 0.000 abstract 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 abstract 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 abstract 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UNA DISPERSION SOLIDA AMORFA DE 1-[5-(4-AMINO-7-ISOPROPIL-7H-PIRROLO[2,3-d]PIRIMIDIN-5-CARBONIL)-2-METOXI-FENIL]-3-(2,4-DICLORO-FENIL)-UREA Y UN POLIMERO PARA AUMENTAR LA CONCENTRACION TAL COMO ACETATO SUCCINATO DE HIDROXIPROPIL METILCELULOSA, EN DONDE DICHO COMPUESTO DE UREA COMPRENDE ENTRE 10% Y 40% EN PESO DE LA DISPERSION SOLIDA AMORFA. DICHA DISPERSION SOLIDA AMORFA ESTA MEZCLADA CON MAS POLIMEROS PARA AUMENTAR LA CONCENTRACION TALES COMO ACETATO DE HIDROXIPROPIL METIL CELULOSA, HIDROXIPROPIL METIL CELULOSA, HIDROXIPROPIL CELULOSA, METIL CELULOSA, HIDROXIETIL METIL CELULOSA, ENTRE OTROS. DICHA COMPOSICION FARMACEUTICA ES UTIL PARA EL TRATAMIENTO DE TRASTORNOS HIPERPROLIFERATIVOSREFERRING TO A PHARMACEUTICAL COMPOSITION INCLUDING AN AMORPHOUS SOLID DISPERSION OF 1- [5- (4-AMINO-7-ISOPROPIL-7H-PYRROLO [2,3-d] PYRIMIDIN-5-CARBONYL) -2-METOXY-PHENYL] - 3- (2,4-DICHLORO-PHENYL) -UREA AND A POLYMER TO INCREASE THE CONCENTRATION SUCH AS HYDROXYPROPYL METHYLCELLULOSE ACETATE SUCCINATE, WHERE SAID UREA COMPOUND INCLUDES BETWEEN 10% AND 40% BY WEIGHT OF THE DISPERSION SOLID. SAID AMORPHOUS SOLID DISPERSION IS MIXED WITH MORE POLYMERS TO INCREASE THE CONCENTRATION SUCH AS HYDROXYPROPYL METHYL CELLULOSE ACETATE, HYDROXYPROPYL METHYL CELLULOSE, HYDROXYPROPYL CELLULOSE, METHYL CELLULOSE, METHYL CELLULOSE. SAID PHARMACEUTICAL COMPOSITION IS USEFUL FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74907005P | 2005-12-09 | 2005-12-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20071037A1 true PE20071037A1 (en) | 2007-11-19 |
Family
ID=38123252
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006001565A PE20071037A1 (en) | 2005-12-09 | 2006-12-06 | SALTS AND FORMULATIONS OF 1- [5- (4-AMINO-7-ISOPROPYL-7H-PYRROLO [2,3-d] PYRIMIDIN-5-CARBONYL) -2-METOXY-PHENYL] -3- (2,4-DICHLORO -PHENIL) -UREA |
Country Status (8)
| Country | Link |
|---|---|
| AR (1) | AR058293A1 (en) |
| DO (1) | DOP2006000271A (en) |
| GT (1) | GT200600496A (en) |
| NL (1) | NL2000337A1 (en) |
| PE (1) | PE20071037A1 (en) |
| TW (1) | TW200733965A (en) |
| UY (1) | UY29991A1 (en) |
| WO (1) | WO2007066189A2 (en) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY31406A1 (en) * | 2007-10-19 | 2009-05-29 | "SOLID DISPERSION PRODUCT CONTAINING A N-ARIL UREA BASED COMPOUND". | |
| PA8800101A1 (en) * | 2007-10-19 | 2009-05-15 | Abbott Gmbh & Co Kg | SOLID DISPERSION PRODUCT CONTAINING A N-ARIL UREA-BASED COMPOUND |
| AU2009305669A1 (en) * | 2008-10-16 | 2010-04-22 | The Regents Of The University Of California | Fused ring heteroaryl kinase inhibitors |
| PH12012501337A1 (en) | 2009-12-30 | 2012-12-17 | Arqule Inc | Substituted pyrrolo-aminopyrimidine compounds |
| WO2011163090A1 (en) * | 2010-06-23 | 2011-12-29 | Metabolex, Inc. | Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| MX370814B (en) | 2011-09-02 | 2020-01-08 | Univ California | Substituted pyrazolo[3,4-d]pyrimidines and uses thereof. |
| US20140004192A1 (en) * | 2012-04-13 | 2014-01-02 | Ziopharm Oncology, Inc. | Pharmaceutical formulations of indibulin and uses thereof |
| UA125503C2 (en) | 2012-06-13 | 2022-04-13 | Інсайт Холдинґс Корпорейшн | Substituted tricyclic compounds as fgfr inhibitors |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| SG11201502331RA (en) | 2012-09-26 | 2015-04-29 | Univ California | Modulation of ire1 |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| WO2014172644A2 (en) | 2013-04-19 | 2014-10-23 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| UA121669C2 (en) | 2015-02-20 | 2020-07-10 | Інсайт Корпорейшн | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS |
| MA41551A (en) | 2015-02-20 | 2017-12-26 | Incyte Corp | BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS |
| CN107722012B (en) * | 2016-08-11 | 2020-05-29 | 斯福瑞（南通）制药有限公司 | Process for preparing 4-chloro-7H-pyrrolo [2,3-d ] pyrimidines |
| AR111960A1 (en) | 2017-05-26 | 2019-09-04 | Incyte Corp | CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION |
| SI3788047T1 (en) | 2018-05-04 | 2024-11-29 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
| CN112566912A (en) | 2018-05-04 | 2021-03-26 | 因赛特公司 | Salts of FGFR inhibitors |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| EP4045151A1 (en) | 2019-10-14 | 2022-08-24 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| EP4069695A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Derivatives of an fgfr inhibitor |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US12065494B2 (en) | 2021-04-12 | 2024-08-20 | Incyte Corporation | Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent |
| WO2022261160A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| CA3220155A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| JP2025015449A (en) * | 2023-07-18 | 2025-01-30 | 信越化学工業株式会社 | Composition for solid dispersion, solid dispersion, and method of manufacturing solid dispersion |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT901786E (en) * | 1997-08-11 | 2007-08-07 | Pfizer Prod Inc | Solid pharmaceutical dispersions with enhanced bioavailability |
| UA80171C2 (en) * | 2002-12-19 | 2007-08-27 | Pfizer Prod Inc | Pyrrolopyrimidine derivatives |
-
2006
- 2006-11-24 WO PCT/IB2006/003416 patent/WO2007066189A2/en not_active Ceased
- 2006-11-27 NL NL2000337A patent/NL2000337A1/en active Search and Examination
- 2006-12-05 DO DO2006000271A patent/DOP2006000271A/en unknown
- 2006-12-06 UY UY29991A patent/UY29991A1/en not_active Application Discontinuation
- 2006-12-06 PE PE2006001565A patent/PE20071037A1/en not_active Application Discontinuation
- 2006-12-07 GT GT200600496A patent/GT200600496A/en unknown
- 2006-12-07 AR ARP060105422A patent/AR058293A1/en unknown
- 2006-12-08 TW TW095145947A patent/TW200733965A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007066189A2 (en) | 2007-06-14 |
| GT200600496A (en) | 2007-07-17 |
| TW200733965A (en) | 2007-09-16 |
| DOP2006000271A (en) | 2007-08-15 |
| AR058293A1 (en) | 2008-01-30 |
| NL2000337A1 (en) | 2007-06-12 |
| WO2007066189A3 (en) | 2008-08-14 |
| UY29991A1 (en) | 2007-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20071037A1 (en) | SALTS AND FORMULATIONS OF 1- [5- (4-AMINO-7-ISOPROPYL-7H-PYRROLO [2,3-d] PYRIMIDIN-5-CARBONYL) -2-METOXY-PHENYL] -3- (2,4-DICHLORO -PHENIL) -UREA | |
| MA29851B1 (en) | COMPOUNDS AND COMPOSITIONS CONTAINING DIARYLAMINE AND USE AS MODULATORS OF C-KIT RECEPTORS | |
| UY31870A (en) | METABOTROPIC RECEIVER OF POTENTIAL GLUTAMATE 286 | |
| NI200700064A (en) | NEW PHARMACEUTICAL COMPOSITIONS THAT INCLUDE ACID 4- (4- (3- (4-CHLORINE-3- TRIFLUOROMETIL-PHENYL) - UREIDO) -3-FLUORO-PHENOXI) -PIRIDIN-2-CARBOXYLIC FOR THE TREATMENT OF HYPERPROLIFERAL DISORDERS. | |
| CL2009000662A1 (en) | Trisubstituted 1,2,4-triazole derivative compounds, modulators of the nicotinic acetylcholine receptor; pharmaceutical composition; its preparation process; and use for the prevention or treatment of psychotic disorders, intellectual impairment disorders or diseases, or inflammatory diseases or disorders. | |
| CY1115058T1 (en) | 1,2,3-TRIZOLIS PRODUCT FOR USE AS STEATOILO-COA SUSPENSIONS | |
| CR11441A (en) | SOLID DISPERSION PRODUCT CONTAINING A N-ARIL UREA-BASED COMPOUND | |
| UY31080A1 (en) | PIRAZOL DERIVATIVES REPLACED WITH HETEROARILE USEFUL TO TREAT HYPERPROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | |
| UY31219A1 (en) | N- [3- (2,6-DICLOROPHENIL) -5-ALQUILO-1,2-OXAZOL-4-IL SUBSTITUTED CARBAMATES AND 1- [3- (2,6-DICLOROPHENYL) -5-METHYL-1,2- OXAZOL-4-IL] SUBSTITUTED UREAS AS WELL AS ISOMEROS, PHARMACEUTICAL SALTS AND USES OF SUCH COMPOUNDS | |
| UY31079A1 (en) | PHENYLAMINOBENCENE DERIVATIVES SUBSTITUTED FOR USE FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH EXTRACELLULAR KINASE ACTIVITY MEDITATED BY MYTHOGENS | |
| PE20070720A1 (en) | DERIVATIVES OF PHENYL AS ANTAGONISTS OF HISTAMINE RECEPTOR 3 | |
| CL2008001465A1 (en) | Compounds derived from [2,1,3] benzoxadiazole-5-carboxamides, modulators of ampa receptors; pharmaceutical compositions; and its use in the treatment of hypoglutamatergic conditions, cognitive disorders, parkinson's disease, adhd, rett syndrome, respiratory depression, fragile x syndrome, and Alzheimer's disease. | |
| AR060536A1 (en) | GLUCOCORTICOID RECEPTOR AGONIST AND PHARMACEUTICAL COMPOSITIONS | |
| UY30316A1 (en) | SUBSTITUTED DERIVATIVES OF BENZAMIDS, NICOTINAMIDS, PROPANAMIDS, ACETAMIDS AND CARBOXAMIDS N- (2- (PIPERIDIN-1-ILMETIL) CICLOHEXIL) REPLACED, PREPARATION PROCESSES, COMPOSITIONS CONTAINING AND APPLICATIONS | |
| ECSP088829A (en) | BENCIMIDAZOL 5-SULFONAMIDE DERIVATIVES AS CANNABINOID 1 RECEPTOR LIGANDS (CB1) | |
| AU2009287650A8 (en) | Hair growth promoting agent containing 15,15 -difluoroprostaglandin F2alpha derivative as active ingredient | |
| AR055319A1 (en) | ISOQUINOLEIN DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES | |
| WO2008074833A3 (en) | Compounds | |
| CL2009001267A1 (en) | Compounds derived from nitrogenous tricycles, with antibacterial activity; preparation procedure; pharmaceutical composition comprising them; for the treatment of tuberculosis. | |
| EA201000926A1 (en) | PIPERASINS AS AGENTS AGAINST OBESITY | |
| PL1843754T3 (en) | New pharmaceutical composition containing candesartan cilexetil as lipophilic crystalline substance | |
| NO20073702L (en) | Non-steroid glucocorticoid receptor modulators | |
| DE502006003194D1 (en) | SALTS OF SUBSTITUTED ALLOPHANIC ACID ESTERS AND THEIR USE IN MEDICINAL PRODUCTS | |
| IN266834B (en) | ||
| UY28917A1 (en) | DERIVATIVES OF TETRAHYDROISOQUINOLILSULFONAMIDS PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC USE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |